“The nasal vaccine is a two—component. If the primary vaccination, then two components are used, and if as a booster, then one component,” he said.
Earlier, Denis Logunov, deputy head of the Gamalea Center, said that the nasal vaccine from COVID-19 “Sputnik V” is painless, has a minimum of side effects, and will create an additional barrier in the form of immunity in the upper respiratory tract.
In early November, Ginzburg reported that an additional nasal vaccine vaccinated against COVID-19 would not be a vector of the virus.
The Gamalei Center has already developed several vaccines for the prevention of COVID-19: Sputnik V, which has shown high efficiency and safety and has already been approved in more than 70 countries, Sputnik Lite, designed primarily for revaccination, and Sputnik M, for adolescents.
In addition, EpiVacCorona, created in the Novosibirsk Vector Center, and KoviVak, developed by the Chumakov Center of the Russian Academy of Sciences, are used in Russia.
Vaccination remains the most reliable way to protect against coronavirus. According to the head of the Russian Ministry of Health Mikhail Murashko, the proportion of vaccinated among COVID-19 cases does not exceed four percent, severe cases are few, while the vast majority of patients in hospitals are unvaccinated. At the end of September in The WHO stated that mortality from SARS-CoV-2 was associated with the refusal of preventive immunization.